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Summary
 
The herpes simplex virus (HSV) infected cell protein (ICP)47 blocks CD8
 
1
 
 T cell recognition
of infected cells by inhibiting the transporter associated with antigen presentation (TAP). In
vivo, HSV-1 replicates in two distinct tissues: in epithelial mucosa or epidermis, where the vi-
rus enters sensory neurons; and in the peripheral and central nervous system, where acute and
subsequently latent infections occur. Here, we show that an HSV-1 ICP47
 
2
 
 mutant is less neu-
rovirulent than wild-type HSV-1 in mice, but replicates normally in epithelial tissues. The re-
duced neurovirulence of the ICP47
 
2
 
 mutant was due to a protective CD8
 
1
 
 T cell response.
When compared with wild-type virus, the ICP47
 
2
 
 mutant expressed reduced neurovirulence
in immunologically normal mice, and T cell–deficient nude mice after reconstitution with
CD8
 
1
 
 T cells. However, the ICP47
 
2
 
 mutant exhibited normal neurovirulence in mice that
were acutely depleted of CD8
 
1
 
 T cells, and in nude mice that were not reconstituted, or were
reconstituted with CD4
 
1
 
 T cells. In contrast, CD8
 
1
 
 T cell depletion did not increase the neu-
rovirulence of an unrelated, attenuated HSV-1 glycoprotein (g)E
 
2
 
 mutant. ICP47 is the first
viral protein shown to influence neurovirulence by inhibiting CD8
 
1
 
 T cell protection.
 
H
 
erpesviruses are particularly adept at avoiding detec-
tion by CD8
 
1
 
 T lymphocytes. They often express
several proteins that can independently block the MHC
class I presentation pathway by which antigenic peptides
are presented to CD8
 
1
 
 T cells. This immune evasion might
be particularly important to a family of viruses that persists
or establishes latent infections, often for the lifetime of an
infected individual. During reactivation from the latent
state, herpesviruses encounter robust, fully primed immune
systems. Thus, immune evasion is probably important to
reduce the effects of antiviral immunity until progeny can be
produced. Herpes simplex virus (HSV)
 
1
 
 infected cell pro-
tein (ICP)47 blocks the transporter associated with antigen
presentation (TAP), so that antigenic peptides cannot be
transported into the endoplasmic reticulum, the site of as-
sembly of MHC class I molecules (1–5). Another human
herpesvirus, human cytomegalovirus, encodes at least five
polypeptides that each independently inhibit the MHC class
I presentation pathway (6–11). To explain this apparent re-
dundancy, it has been suggested that these viral gene prod-
ucts can act in distinct tissue types to provide resistance to
CD8
 
1
 
 T cells (5, 8). However, this has not been tested and
in no case has an in vivo effect of one of these herpesvirus
proteins been established.
We used a murine ocular model of HSV infection to test
the effects of ICP47 on viral pathogenesis. This model has
been used extensively to study HSV corneal infection, a
disease that is still a leading cause of blindness. HSV-1 in-
fection of the cornea leads to virus replication and transmission
to several tissues, accompanied by leukocytic infiltration in
the following sequence: (
 
a
 
) lesions develop in the epithelial
layer of the cornea after 2 d, accompanied by predomi-
nantly PMN infiltration. These lesions heal within 2–3 d in
both immunologically normal and T cell–deficient mice
(12), suggesting that T cells are not important for limiting
this primary disease. (
 
b
 
) During infection of the corneal ep-
ithelium, sensory neurons that have cell bodies in the
trigeminal ganglia become infected. In ganglia, HSV-1 rep-
lication can be detected in sensory neurons, satellite cells,
and Schwann cells from 2–8 d after infection, but then la-
tency is established in neurons. However, with some strains
of HSV-1, latency is incomplete, and the virus can spread
from ganglia to the central nervous system and cause en-
cephalitis. CD8
 
1
 
 T cells play an important role in control-
ling the duration of HSV-1 replication in sensory ganglia
 
1
 
Abbreviations used in this paper:
 
 gE, glycoprotein E; HSV, herpes simplex
virus; ICP, infected cell protein; TAP, the transporter associated with an-
tigen presentation.
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and preventing transmission to the central nervous system
(13). (
 
c
 
) About 7 d after infection, mice develop lesions in
the skin surrounding the eyelids. These lesions are signifi-
cantly exacerbated in T cell–deficient mice (14), and it ap-
pears that CD4
 
1
 
 and CD8
 
1
 
, 
 
a
 
/
 
b
 
 TCR
 
1
 
 T cells (15, 16),
and 
 
g
 
/
 
d
 
 TCR
 
1
 
 T cells (14) are important for protection
from HSV-1 skin lesions. Approximately 10–14 d after in-
fection, inflammation develops in the stromal layer of the
cornea, and is regulated by CD4
 
1
 
 T lymphocytes (17, 18)
through the elaboration of the cytokines IFN-
 
g
 
 and IL-2
(19–22). Therefore, HSV disease in this animal model is
controlled by different T cell subsets in different tissues, but
in the nervous system CD8
 
1
 
 T cells are particularly impor-
tant.
A major consideration in using the mouse model to
study the effect of ICP47 on HSV pathogenesis is the pre-
vious observations that ICP47 inhibits the murine TAP rel-
atively poorly (3, 4, 23). Inhibition of TAP activity in
mouse fibroblasts required ICP47 concentrations 50–100-
fold higher than those required to inhibit TAP in human
fibroblasts. These studies might militate against the use of a
mouse model to study the ICP47 effect on virus virulence.
However, our initial studies suggested that an ICP47
 
2
 
HSV mutant was less virulent in the mouse nervous system.
This apparent incongruity may relate to the prominent
protective role of HSV-reactive CD8
 
1
 
 T cells in the pe-
ripheral nervous system, and the low levels of MHC class I
expression in the nervous system. Neurons are deficient in
antigen presentation, expressing little or no MHC class I on
their surface (24–26). However, low levels of MHC class I
proteins are expressed in satellite cells and Schwann cells,
which also become infected in sensory ganglia, and class I
may be upregulated by HSV infection of these accessory
cells (25). Therefore, it was reasonable to postulate that
ICP47 might block recognition of HSV-infected host cells
by CD8
 
1
 
 T cells in the nervous system, in a manner that
cannot be discerned in assays involving cultured mouse fi-
broblasts. Indeed, our current findings support this hypoth-
esis by demonstrating that an HSV-1 ICP47 deletion mu-
tant exhibits dramatically reduced neurovirulence in mice
with functional CD8
 
1
 
 T cells, but normal neurovirulence
in CD8
 
1
 
 T cell–deficient mice.
 
Materials and Methods
 
Viruses and Construction of an HSV-1 ICP47-mutant.
 
The wild-
type HSV-1 strain F was obtained from Dr. Patricia Spear, North-
western University, Chicago, IL. This virus was plaque-purified
twice before construction of mutant viruses, and was propagated
on Vero cell monolayers. Contruction of an HSV-1 glycoprotein
E deletion mutant (F-gE
 
b
 
) has been previously described (27).
To contstruct an ICP47
 
2
 
 HSV-1, a deletion of 
 
z
 
10 nucleotides
was introduced between an EcoNI site upstream of the ICP47
start codon and two adjacent BsiWI sites in plasmid pBR421
(28). This deletion removed the ICP47 start codon and two
downstream ATG codons in the protein, and did not affect the
promoter of the adjacent US11 gene. A plasmid containing this
deletion was cotransfected with DNA derived from HSV-1 strain
F into Vero cells as previously described (29). Using PCR to ana-
lyze viral DNA, viruses derived from the transfection were
screened for the 10 nucleotide deletion. A virus, denoted F-ICP47
 
D
 
,
contained the expected deletion, as confirmed by Northern blots
of viral DNA. F-ICP47
 
D
 
 expressed US11 protein, but did not
express ICP47. F-ICP47
 
D
 
 was plaque purified two additional
times. To rule out the possibility of additional mutations in
F-ICP47
 
D
 
, a rescued virus, able to express ICP47, was derived
from F-ICP47
 
D
 
. Vero cells were cotransfected with F-ICP47
 
D
 
DNA and a plasmid, PRB421, containing wild-type ICP47 and
US11 genes (28). Viruses derived from this transfection were
screened by PCR and a virus, which expressed ICP47, denoted
F-ICP47
 
D
 
R, and US11 was plaque purified two additional times.
 
Characterization of Viruses for ICP47 and US11 Expression.
 
To ascertain whether viruses expressed ICP47 and US11, human
R970 cells were infected with wild-type HSV-1 F, F-ICP47
 
D
 
, or
F-ICP47
 
D
 
R. The cells were labeled with [
 
35
 
S]-methionine, 3–6 h
after infection for ICP47, or 7–10 h after infection for US11 ex-
pression. Cell extracts were prepared and immunoprecipitated as
previously described (23). Anti-ICP47 serum was produced in
rabbits injected with recombinant ICP47 from bacteria (4, 23).
Anti-US11 serum has been previously described (30) and was the
generous gift of Dr. Bernard Roizman, (University of Chicago,
Chicago, IL).
 
Virus Inoculation and Evaluation of Disease.
 
Female A/J, BALB/c,
or BALB/c athymic nude mice (Frederick Cancer Research, Fred-
erick, MD), 6–8 wk of age, were anesthetized by intramuscular
injection of 2.0 mg of ketamine hydrochloride (Vetalar; Parke-
Davis, Morris Plains, NJ) and 0.04 mg of acepromazine maleate
(Aveco Co., Fort Dodge, IA) in 0.1 ml of HBSS. The F strain of
HSV-1, F-ICP47
 
D
 
, F-ICP47
 
D
 
R, and the gE deletion mutant
F-gE
 
b
 
 (27) were grown in Vero cells, and intact virions were pu-
rified on Percoll (Pharmacia Biotech, Piscataway, NJ) as previ-
ously described (31). For each experiment, the virus samples were
coded so that the person infecting the corneas and evaluating the
corneal disease did not know which virus was used to infect the
cornea. Corneas of anesthetized mice were scarified 10 times in a
crisscross fashion with a sterile 30 gauge needle, and the eyes were
infected topically with 3 
 
m
 
l of PBS containing varying amounts
of HSV-1, as specified in the text. Mice were treated with 0.3%
gentamicin sulfate ophthalmic solution (Genoptic; Allergen
America, Puerto Rico) topically from days 4 to 11 after infection
to prevent secondary bacterial infection.
Corneal epithelial disease was evaluated by instilling fluo-
rescene drops on the eye and examining the cornea with a slit-
lamp biomicroscope with a cobalt blue filter in the light path.
HSV-1 replication in corneal epithelial cells results in pathogno-
monic dendritic-shaped lesions that stain with fluorescene. The
severity of epithelial lesions was scored by a masked observer us-
ing a scale of 0 to 4
 
1
 
, where 1
 
1
 
 
 
5
 
 punctate lesion; 2
 
1
 
 
 
5
 
 den-
dritic lesion; 3
 
1
 
 
 
5
 
 dendritic lesion with an amorphous central
loss of epithelium; and 4
 
1
 
 
 
5
 
 dendritic lesion with an amorphous
central loss of epithelium that occupies 
 
.
 
25% of the area of the
cornea.
Corneal stromal inflammation was evaluated with a slit lamp
on the basis of corneal opacity on a scale of 0 to 4
 
1
 
 as previously
described (21). Periocular skin disease was scored on a scale of 0
to 5
 
1
 
, where 1
 
1
 
 
 
5
 
 blepharitis (eyelid only); 2
 
1
 
 
 
5
 
 
 
,
 
2 mm of
fur loss around the eye, and no observable vesicles, 3
 
1
 
 
 
5
 
 
 
,
 
2
mm of fur loss with vesicles, 4
 
1
 
 
 
5
 
 
 
.
 
2 mm of fur loss around the
eye, without vesicles; and 5
 
1
 
 
 
5
 
 
 
.
 
2 mm of fur loss around the
eye with vesicles. The manifestations of neurologic disease in-
cluded weight loss, ruffled fur, paralysis, and death. 
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HSV Titration in the Infected Cornea.
 
Groups of 10 mice re-
ceived unilateral corneal infections with either 10
 
5
 
 or 10
 
4
 
 PFU of
wild-type HSV-1, F-ICP47
 
D
 
, or F-ICP47
 
D
 
R. 2 d later, the cor-
neas were sterilely excised and frozen at 
 
2
 
70
 
8
 
C until the time of
assay. On the day of assay, the corneas were individually homog-
enized, submitted to three freeze–thaw cycles, and sonicated. The
extracts were then centrifuged at 4,000 rpm for 30 min in a mi-
crocentrifuge, and the supernatant was assayed for infectious virus
particles in a standard plaque assay on Vero cells.
 
In Vivo CD8
 
1
 
 T Lymphocyte Depletion.
 
Groups of A/J mice
received intraperitoneal injections of 50 
 
m
 
g of rat mAbs specific
for CD8-
 
a
 
 (clone 2.43; American Type Culture Collection,
[ATCC], Rockville, MD), or a similar dose of rat mAb to HLA-
DR5 (clone SFR3-DR5; ATCC) as a control. Both mAbs were
purified on a protein G–Sepharose Fastflow column (Pharmacia
Biotech) and quantified with a radial immunodiffusion kit (ICN
Flow Laboratories; Costa Mesa, CA). The mAb treatments were
given 1 day before infection, and 2, 6, and 12 d after infection.
 
LD
 
50
 
 Assay in Athymic Nude Mice.
 
Groups of 6 female BALB/c
athymic nude mice received corneal infections with various doses
of F-ICP47
 
D
 
, F-ICP47
 
D
 
R, or the wild-type F strain of HSV-1,
and survival time was recorded during a 30-d observation period.
 
T Cell Reconstitution of Nude Mice.
 
The corneas of euthymic
BALB/c donor mice were infected with 10
 
5
 
 PFU of HSV-1. 5 d
later, the mice were depleted of CD4
 
1
 
 or CD8
 
1
 
 T lymphocytes
by intraperitoneal injection of 250 
 
m
 
g of mAb to mouse CD4
(clone GK1.5; ATCC) or 50 
 
m
 
g of mAb to CD8-
 
a
 
 (clone 2.43).
2 d later, draining LN cells were prepared and stimulated over-
night with UV-inactivated HSV-1. The next day, the enriched
CD41 or CD81 cells were further purified by negative selection
with anti-CD4– or anti-CD8–coated magnetic beads (Dynal Inc.,
Lake Success, NY). This procedure routinely yielded LN cell
populations in which 98–100% of the T lymphocytes were CD41
or CD81 as assessed by flow cytometry.
BALB/c athymic nude recipient mice were infected with
F-ICP47D or F-ICP47DR HSV-1. 6 d after infection, the mice
were reconstituted by a single intraperitoneal injection of 1.5 3
107 of the highly enriched CD41 or CD81 T lymphocytes, and
the course of the disease was followed.
Results
ICP47 Does Not Affect HSV-1–induced Corneal Epithelial Dis-
ease, Stromal Inflammation, or Periocular Skin Disease. Groups
of 10 A/J mice received uniocular corneal infections with
two different doses of wild-type HSV-1 strain F, F-ICP47D,
or F-ICP47DR. The generation and characterization of the
mutant viruses is shown diagrammatically in Fig. 1, and de-
scribed in detail in Materials and Methods. 2 d after infec-
tion, all mice developed dendritic-shaped corneal epithelial
lesions similar to those observed with wild-type HSV-1
(data not shown). As shown in Table 1, the severity of the
corneal epithelial lesions was dose dependent, and the le-
sions caused by F-ICP47D were similar in magnitude to
those caused by wild-type and F-ICP47DR when scored
by a masked observer. Moreover, the yields of virus from
corneas infected with F-ICP47D, F-ICP47DR, or wild-
type HSV-1 did not differ (P 5 0.79). At the higher doses
of virus, corneal stromal inflammation and periocular skin
disease were difficult to compare because most mice in-
fected with F-ICP47DR or wild-type HSV-1 died of en-
cephalitis. However, in mice infected with a sublethal dose
(104 PFU) of wild-type F, F-ICP47D, or F-ICP47DR, there
was a 50–60% incidence of stromal disease (data not
shown), and the severity of this inflammation did not differ
significantly (P 5 0.18, Table 1). An equivalent number of
mice infected with wild-type F, F-ICP47D, or F-ICP47DR
developed vesicular skin lesions surrounding the eye and
these lesions were of a similar magnitude (P 5 0.63, Table
Table 1. Effect of ICP47 on HSV-1 Corneal and Skin Disease Severity
Infection*
Corneal Disease
Skin Disease Epithelial‡ Stromal§
Virus Yieldi
(PFU 3 103) Strain Dose (PFU)
mean 6 SEM mean 6 SEM mean 6 SEM mean 6 SEM
Wild-type 1.0 3 105 3.0 6 0 N/A** 5.7 6 1.6 N/A
Wild-type 1.0 3 104 1.2 6 0.4 2.4 6 2.1 4.9 6 2.6 2.4 6 1.0
F-ICP47D 1.0 3 105 3.0 6 0 2.3 6 2.0 4.1 6 1.3 2.2 6 1.0
F-ICP47D 1.0 3 104 1.1 6 0.3 2.8 6 2.9 3.2 6 1.9 2.2 6 1.0
F-ICP47DR 1.0 3 105 3.0 6 0 N/A 3.9 6 1.9 N/A
F-ICP47DR 1.0 3 104 1.2 6 0.4 2.7 6 1.7 3.6 6 2.7 2.4 6 1.6
*One cornea of each mouse was infected with HSV-1 F strain (wild-type), and ICP47 deletion mutant derived from F (F-ICP47D), or a revertant of 
ICP47D (F-ICP47DR).
‡Size of the epithelial lesion, scored on a scale of 0–41.
§Degree of corneal opacity, scored on a scale of 0–41.
iCorneas were excised 2 d after infection, and extracted virus was quantified in a standard plaque assay.
¶Severity of periocular skin disease scored on a scale of 0–51.
**Mice died before disease fully developed.344 ICP47 Augments Herpes Simplex Virus Neurovirulence
1). Therefore, ICP47 does not significantly impact HSV-1
replication and virulence in the eye or in the periocular
skin.
ICP47 Does Influence HSV-1 Neurovirulence and Lethality
in the Mouse. In contrast to the effects seen in the skin and
eye, the ICP472 mutant was less able to cause neurologic
symptoms and death. In 3 experiments, each involving 10
mice, 80% of the mice infected with wild-type HSV-1 ex-
perienced hind limb paralysis and loss of motor coordina-
tion along with ruffled fur and obvious weight loss by 10 d,
and 76% succumbed to the infection by day 12 (Fig. 2).
Similarly, 68% of the mice infected with F-ICP47DR
showed neurologic symptoms and 61% died by day 13 (Fig.
2). By contrast, only 24% of the mice infected with F-ICP47D
displayed neurologic symptoms and died of the infection
(Fig. 2).
ICP47 Augments HSV-1 Neurovirulence in the Presence, but
not in the Absence, of CD81 T Lymphocytes. To determine
if CD81 T cells were responsible for the reduced neurovir-
ulence of F-ICP47D, mice were depleted of CD81 T cells
by treatment with anti-CD8-a mAb, as described in the
Materials and Methods section. This treatment protocol
routinely resulted in .98% depletion of CD81 cells in LN
as assessed by flow cytometric analysis. As shown in Fig. 2,
CD81 T cell depletion dramatically increased neurological
disease and mortality in mice infected with F-ICP47D, but
had little effect on the mortality caused by wild-type HSV-1
or F-ICP47DR.
A gE-mutant (F-gEb), also derived from the HSV-1 F
strain, is also compromised in its ability to induce encepha-
litis in immunologically normal mice (27). However,
CD81 T cell depletion did not increase the neurovirulence
of F-gEb (Fig. 2). Thus, although deletion of several HSV
genes can reduce neurovirulence, ICP47 is unique in that
its effect on neurovirulence is only seen in the presence of
functional CD81 T lymphocytes.
To determine whether CD41 T cells contribute to the
reduced neurovirulence, we initially attempted similar in
vivo depletion experiments involving an anti-CD4 mAb,
but these studies were inconclusive because depletion of
CD41 T cells caused significant reductions in CD81 T cell
infiltration into ganglia (data not shown). We chose to cir-
cumvent this problem by performing adoptive transfers
into athymic nude mice. The LD50 of F-ICP47D (2,014
PFU) was not significantly different from the LD50 of
F-ICP47DR (1,596 PFU) in nude mice (Fig. 3). Thus,
ICP47 does not alter virus replication or neurovirulence in
the absence of T lymphocytes.
Figure 1. Generation of an HSV-1 ICP47 deletion mutant. The ge-
nome of HSV-1 is depicted in the upper panel of the figure. A 100-
nucleotide deletion in the HSV US12 gene, which encodes ICP47, was
created. The deletion removes the ICP47 start codon and two down-
stream ATG codons, but does not affect the promoter of the adjacent
US11 gene. Cells were cotransfected with a plasmid containing the dele-
tion, and viral DNA derived from HSV-1 (strain F). Virus progeny were
screened for the mutation by performing PCR on samples of viral DNA.
A virus, denoted F-ICP47D, contained the deletion in the US12 gene. A
rescued derivative of F-ICP47D, denoted F-ICP47DR, was produced by
cotransfecting cells with F-ICP47D DNA and a plasmid containing the
wild-type US12 gene. In the lower panel, cells were infected with wild-
type HSV-1, F-ICP47D, or F-ICP47DR, then radiolabeled with [35S]me-
thionine. ICP47 was immunoprecipitated from cell extracts using a rabbit
anti-ICP47 serum, and US11 protein was immunoprecipitated using an
anti-US11 serum.
Figure 2. ICP47 enhances
neurovirulence in mice. In 3 ex-
periments, groups of 10 female
A/J mice were depleted of
CD81 T cells by injection of
anti-CD8 mAb (solid bars), or
were mock depleted by injection
of control mAb (gray bars). The
mice received uniocular corneal
infections with 105 PFU of wild-
type HSV-1 F strain, F-ICP47D, or F-ICP47DR, or F-gEb. The survival
rate was determined after a 30-d observation period, although all deaths
occurred 12–14 d after infection. The *** indicates that the survival rate
was significantly increased (P , 0.001) in immunologically normal mice
infected with the F-ICP47D deletion mutant when compared with one
of the following: CD81 T cell–depleted mice infected with F-ICP47D;
immunologically normal mice infected with wild-type F; or immunolog-
ically normal mice infected with F-ICP47DR.
Figure 3. ICP47 does not en-
hance neurovirulence in T cell–
deficient mice. Groups of six
BALB/c athymic nude mice re-
ceived corneal infections with
various doses of F-ICP47D (m)
or F-ICP47DR (h). The mor-
tality rate was observed over a
30-d observation period. The
symbols represent the percentage
of mortality at each infectious dose. The linear regression lines are shown
for each data set. There is no significant difference in the slopes (P 5
0.6604) or the elevations and intercepts (P 5 0.3738) of the two lines.345 Goldsmith et al.
To determine whether CD41 and CD81 T cells influ-
enced neurovirulence, highly enriched populations of CD41
or CD81 T cells, obtained from the LNs of HSV-infected
mice, were transferred into nude mice. Adoptive transfer
of CD81 T cells significantly enhanced the survival of
F-ICP47D–infected mice, but did not significantly alter
survival of F-ICP47DR–infected mice (Fig. 4). Adoptive
transfer of CD41 T cells did not significantly influence the
survival of mice that were infected with either virus. These
data clearly establish that ICP47 augments HSV neuroviru-
lence in mice by specifically inhibiting a protective CD81
T cell response. With ICP47 in place, the F strain of HSV-1 is
relatively resistant to the effects of CD81 cells in the ner-
vous system.
Discussion
CD81 T cells can potentially recognize the broad array of
HSV-1 polypeptides that are produced in virus-infected
cells. However, there is substantial evidence that HSV
avoids detection by CD81 T cells, and the anti-HSV
CD81 T cell response is often weak in humans (for review
see reference 5). ICP47 is an HSV immediate early protein,
expressed very early after infection, that can inhibit CD81
T cell recognition of infected cells (23). Recent studies
have established clearly that ICP47 can bind with high af-
finity to human TAP and inhibit the transport of peptides
into the endoplasmic reticulum (3, 4). The implication of
this finding is that ICP47 can inhibit the expression of HSV
antigens in the context of MHC class I on the surface of in-
fected cells. This is a potentially important adaptation of the
virus to the immune defenses of the host. Unfortunately,
the contribution of ICP47 to viral virulence cannot be
readily determined in humans. Such studies require an ani-
mal model in which both the HSV-1 disease pattern and
the protective effect of T lymphocytes is characterized.
The role of T lymphocytes in controlling the multiple
disease manifestations that result from HSV-1 corneal in-
fection are well characterized. CD81 T cells do not play an
essential role in controlling HSV disease in the cornea or
skin. Corneal epithelial disease is resolved with normal ki-
netics in the absence of CD41 and CD81 T cells (12).
CD41 T cells regulate corneal stromal inflammation (18,
32). Disease in the skin surrounding the eye, which begins
z7 d after the primary infection in the cornea, is controlled
by CD41 or CD81 a/b1 TCR T cells (15, 33), and by g/
d1 TCR T cells (14). However, in the sensory ganglia
CD81 T cells apparently play a dominant role in control-
ling HSV-1 replication and in preventing its transmission to
the central nervous system and subsequent establishment of
lethal encephalitis (13). Thus, it was reasonable to assume
that a viral protein that specifically inhibits CD81 T cell
function might not dramatically affect HSV-1 disease in the
cornea or skin of the mouse, but might nonetheless influ-
ence viral neurovirulence and lethality.
The disease pattern seen in immunologically normal
mice after corneal infection with F-ICP47D HSV-1 was
consistent with the hypothesis that ICP47 confers resistance
to CD81 T cell responses in the nervous system, but is less
effective in the cornea and skin. ICP47 deletion did not in-
fluence the capacity of the virus to replicate in and destroy
corneal epithelial cells. Thus, when compared with the pa-
rental F strain or the F-ICP47DR revertant, the F-ICP47D
mutant produced corneal epithelial lesions of comparable
severity, and similar virus titers were detected in the in-
fected tissue. Moreover, the F-ICP47D mutant, a rescued
version of the mutant, and wild-type HSV-1 all produced
mild skin disease in immunologically normal mice, and se-
vere skin disease in T cell–deficient mice. In contrast to
what was seen at the periphery, the ICP472 HSV caused
little or no neurologic disease and encephalitis, while the
wild-type HSV-1 and the rescued virus killed most animals
after causing encephalitis.
Since CD81 T cells help control virus infection in the
nervous system, one could argue that any HSV mutant that
was “crippled” because it replicated less efficiently, either at
the periphery or in the nervous system, might replicate
better in the absence of CD81 T cells. Although this is pos-
sible, we consider it unlikely for several reasons. First,
HSV-1 thymidine kinase and g34.5 mutants do not cause
neurologic disease or encephalitis in either normal or im-
munologically compromised mice (34, 35). There are de-
fects in replication of these viruses in cells that constitute
the nervous system, and the inability in these viruses to
replicate is not overcome by removing T cells. Second, we
showed here that a gE2 HSV-1 is unable to cause neuro-
Figure 4. Adoptive transfer of CD81,
but not CD41, T cells inhibits neuroviru-
lence of the ICP472 mutant in nude mice.
Groups of five BALB/c athymic nude mice
received corneal infections with 105 PFU of
F-ICP47D HSV-1 (A), or F-ICP47DR
HSV-1 (B). 6 d later, the control group (h)
received no cells, or the mice received 1.5
3 107 lymph node cells from HSV-1–
infected euthymic BALB/c mice that were
highly enriched for CD41 (n) CD81 (s)
T lymphocytes. Survival of the recipient
mice was followed through a 30-d observa-
tion period. Adoptive transfer of CD81
cells conferred a significant survival advantage for mice infected with the F-ICP47D strain (P 5 0.0186), but not for mice infected with the F-ICP47DR
strain (P 5 0.3962). Adoptive transfer of CD41 cells did not significantly alter (P .0.05) survival of mice infected with either virus.346 ICP47 Augments Herpes Simplex Virus Neurovirulence
logic disease whether or not mice are depleted of CD81 T
cells. This mutant can replicate normally in neurons and
other cells, but can not spread efficiently from cell to cell,
and spreads poorly from the eye to the brain (27, 36).
Therefore, it is not surprising that CD81 T cell depletion
cannot rescue this defect. Third, reconstitution with CD41
T cells did not alter the course of disease caused by ICP472
HSV-1 in nude mice. Protection from lethal HSV-1 infec-
tions in mice can be controlled by both CD41 and CD81
T cells, and in one study a dominant role for CD41 cells
was described (16). Therefore, the ICP472 HSV is not just
a “weak” virus with defects in replication that can be over-
come by inhibiting host immunity. Instead, it appears that
ICP47 augments neurovirulence by specifically subverting
a protective CD81 T cell response.
The capacity of HSV ICP47 to block CD81 T cell rec-
ognition of infected target cells varies in different species
and in different types of cells from the same species. Thus,
HSV-infected human B cells and HSV-infected mouse fi-
broblasts are lysed by HSV-specific CTLs, whereas HSV-
infected human fibroblasts are not lysed by the same CTLs
(23). Moreover, the inhibitory effect of ICP47 on CTL
recognition of human fibroblasts could be overcome by ex-
posure of these cells to IFN-g, presumably through its ca-
pacity to augment the basal level of antigen processing and
presentation of these cells (23). These findings suggest that
the capacity of ICP47 to block CD81 T cell protection of
various HSV-infected tissues is determined by a variety of
factors, including: (a) how efficiently ICP47 inhibits TAP
function in that species; (b) the basal level of antigen pro-
cessing and presentation in cells of the infected tissue; and
(c) the cytokine milieu within the infected tissue. HSV-1
ICP47 is a relatively poor inhibitor of murine TAP func-
tion (3, 4). However, in nervous tissue with impaired ca-
pacity to process and present antigens in the context of
MHC class I, even a modest inhibition of TAP function
might have a profound effect on a protective CD81 T cell
response. Assuming a comparable basal level of antigen
processing and presentation in the mouse and human ner-
vous system, one would predict a more profound effect of
ICP47 on HSV-1 neurovirulence in humans due to its in-
creased binding affinity for human TAP.
The mechanism by which CD81 T cells protect HSV-
infected sensory ganglia is not clear. A previous study
showed increased production of MHC class I transcripts in
satellite cells, Schwann cells, and neurons of spinal ganglia
after HSV-1 infection of the skin (24). MHC class I protein
was subsequently expressed on the satellite and Schwann
cells, but not on the neurons. CD81 T cells infiltrate the
trigeminal ganglia of mice z7 d after corneal infection
with wild-type HSV-1, and some are seen in direct apposi-
tion to satellite cells but not neurons in areas of viral anti-
gen expression (37). We propose that direct interaction
with CD81 T cells might result in destruction of the in-
fected satellite cells, but with simultaneous release by the
CD81 cells of antiviral cytokines that control HSV-1 repli-
cation in nearby neurons. This theory is consistent with the
observations that, (a) the cytokines IFN-g and TNF-a can
inhibit HSV replication (38, 39), and (b) these cytokines are
produced in the trigeminal ganglion during acute and latent
infection (37, 40–42). Thus, HSV-specific CD81 T cells
could control virus by cytotoxic mechanisms acting on re-
placeable satellite cells, and by noncytotoxic mechanisms in
neurons that cannot be regenerated.
The effect of ICP47 on the pattern of MHC class I ex-
pression in HSV-1–infected trigeminal ganglia is currently
unknown. By inhibiting the upregulation of MHC class I
expression on satellite cells, ICP47 could reduce the effec-
tiveness of the CD81 T cell response. Alternatively, ICP47
might inhibit the direct interaction of CD81 cells with in-
fected neurons by contributing to the failure of infected
neurons to express MHC class I protein, despite produc-
tion of MHC class I heavy and light chain RNA. Either of
these mechanisms could inhibit CD81 T cell control of
HSV-1 replication in sensory neurons, favoring viral trans-
mission to the brain and induction of lethal encephalitis.
Although the mechanism remains unclear, our data clearly
establish that HSV ICP47 can inhibit a CD81 T cell re-
sponse that prevents lethal encephalitis following from cor-
neal infection.
Wild-type strains of HSV vary markedly in their capacity
to induce neurologic disease in mice. Observations in both
mice (13, 14, 43, 44) and humans (45) have also established
that susceptibility to HSV encephalitis is augmented when
the host immune system is compromised. Thus, resistance
to encephalitis probably results from a balance between the
neurovirulence properties of the infecting virus and the
strength of the host immune response. In general, this bal-
ance is maintained, as encephalitis is rare in humans. Our
studies establish for the first time that HSV can influence
this balance by producing a protein, ICP47, that inhibits an
important host defense mechanism within the nervous sys-
tem. Our results show clearly that a viral immune evasion
strategy can act in a restricted tissue-specific manner and
yet dramatically alter the outcome of disease. In addition,
our observations underscore the difficulties associated with
extrapolating from in vitro biochemical analyses to in vivo
effects on viral disease. Based on studies in mouse fibro-
blasts, one might have predicted that ICP47 would not in-
fluence HSV disease in mice.
This work was supported by National Institutes of Health grants EY-05945 (to R.L. Hendricks), and EY-
11245 (to D.C. Johnson), Core grant EY-01792 (to R.L. Hendricks); an unrestricted research grant from
Research to Prevent Blindness, Inc., New York; and by the Lions of Illinois Foundation, Maywood, IL.
R.L. Hendricks is a Research to Prevent Blindness Senior Scientific Investigator.347 Goldsmith et al.
References
1. Früh, K., K. Ahn, H. Djaballah, P. Sempe, P.M. van Endert,
R. Tampe, P.A. Peterson, and Y. Yang. 1995. A viral inhibi-
tor of peptide transporters for antigen presentation. Nature.
375:415–418.
2. Hill, A., P. Jugovic, I. York, G. Russ, J. Bennink, J. Yewdell,
H. Ploegh, and D. Johnson. 1995. Herpes simplex virus turns
off TAP to evade host immunity. Nature. 375:411–415.
3. Ahn, K., T.H. Meyer, S. Uebel, P. Sempé, H. Djaballah, Y.
Yang, P.A. Peterson, K. Früh, and R. Tampé. 1996. Molec-
ular mechanism and species specificity of TAP inhibition by
herpes simplex virus protein ICP47. EMBO (Euro. Mol. Biol.
Organ.) J. 15:3247–3255.
4. Tomazin, R., A.B. Hill, P. Jugovic, I. York, P. van Endert,
H.L. Ploegh, D.W. Andrews, and D.C. Johnson. 1996. Sta-
ble binding of the herpes simplex virus ICP47 protein to the
peptide binding site of TAP. EMBO (Eur. Mol. Biol. Organ.)
J. 15:3256–3266.
5. Johnson, D.C., and A.B. Hill. 1998. Herpesviruses and im-
mune evasion. Curr. Top. Microbiol. Immunol. In press.
6. Hengel, H., J.O. Koopmann, T. Flohr, W. Muranyi, E.
Goulmy, G.J. Hammerling, U.H. Koszinowski, and F. Mom-
burg. 1997. A viral ER-resident glycoprotein inactivates the
MHC-encoded peptide transporter. Immunity. 6:623–632.
7. Ziegler, H., R. Thale, P. Lucin, W. Muranyi, T. Flohr, H.
Hengel, H. Farrell, W. Rawlinson, and U.H. Koszinowski.
1997. A mouse cytomegalovirus glycoprotein retains MHC
class I complexes in the ERGIC/cis-golgi compartments. Im-
munity. 6:57–66.
8. Ahn, K., A. Gruhler, B. Galocha, T.R. Jones, E.J. Wiertz,
H.L. Ploegh, P.A. Peterson, Y. Yang, and K. Früh. 1997.
The ER-luminal domain of the HCMV glycoprotein US6
inhibits peptide translocation by TAP. Immunity. 6:613–621.
9. Ahn, K., A. Angulo, P. Ghazal, P.A. Peterson, Y. Yang, and
K. Fruh. 1996. Human cytomegalovirus inhibits antigen pre-
sentation by a sequential multistep process. Proc. Natl. Acad.
Sci. USA. 93:10990–10995.
10. Gilbert, M.J., S.R. Riddel, B. Plachter, and P.D. Greenberg.
1996. Cytomegalovirus selectively blocks antigen processing
and presentation of its immediate-early gene product. Nature.
388:720–722.
11. Jones, T.R., L.K. Hanson, L. Sun, J.S. Slater, R.M. Stenberg,
and A.E. Campbell. 1995. Multiple independent loci within
the human cytomegalovirus unique short region down-regu-
late expression of major histocompatibility complex class I
heavy chains. J. Virol. 69:4830–4841.
12. Chen, W., Q. Tang, and R.L. Hendricks. 1996. Ex vivo
model of leukocyte migration into herpes simplex virus–
infected mouse corneas. J. Leukocyte Biol. 60:167–173.
13. Simmons, A., and D.C. Tscharke. 1992. Anti-CD8 impairs
clearance of herpes simplex virus from the nervous system:
implications for the fate of virally infected neurons. J. Exp.
Med. 175:1337–1344.
14. Sciammas, R., P. Kodukula, Q. Tang, R.L. Hendricks, and
J.A. Bluestone. 1997. T cell receptor–g/d cells protect mice
from herpes simplex virus type 1–induced lethal encephalitis.
J. Exp. Med. 185:1969–1975.
15. Smith, P.M., R.M. Wolcott, R. Chervenak, and S.R. Jen-
nings. 1994. Control of acute cutaneous herpes simplex virus
infection: T cell-mediated viral clearance is dependent upon
interferon-g (IFN-g). Virology. 202:76–88.
16. Manickan, E., and B.T. Rouse. 1996. Roles of different
T-cell subsets in control of herpes simplex virus infection de-
termined by using T-cell–deficient mouse models. J. Virol.
69:8178–8179.
17. Newell, C.K., S. Martin, D. Sendele, C.M. Mercadal, and
B.T. Rouse. 1989. Herpes simplex virus–induced stromal
keratitis: role of T-lymphocyte subsets in immunopathology.
J. Virol. 63:769–775.
18. Hendricks, R.L., and T.M. Tumpey. 1990. Contribution of
virus and immune factors to herpes simplex virus type 1 in-
duced corneal pathology. Investig. Ophthalmol. Vis. Sci. 31:
1929–1939.
19. Hendricks, R.L., T.M. Tumpey, and A. Finnegan. 1992.
IFN-g and IL-2 are protective in the skin but pathologic in
the corneas of HSV-1–infected mice. J. Immunol. 149:3023–
3028.
20. Niemialtowski, M., and B. Rouse. 1992. Phenotypic and
functional studies on ocular T cells during herpetic infections
of the eye. J. Immunol. 148:1864–1870.
21. Tang, Q., and R.L. Hendricks. 1996. IFN-g regulates PE-
CAM-1 expression and neutrophil infiltration into herpes
simplex virus–infected mouse corneas. J. Exp. Med. 184:
1435–1447.
22. Tang, Q., W. Chen, and R.L. Hendricks. 1997. Proinflam-
matory functions of IL-2 in herpes simplex virus corneal in-
fection. J. Immunol. 158:1275–1283.
23. York, I.A., C. Roop, D.W. Andrews, S.R. Riddell, F.L.
Graham, and D.C. Johnson. 1994. A cytosolic herpes simplex
virus protein inhibits antigen presentation to CD81 T lym-
phocytes. Cell. 77:525–535.
24. Pereira, R.A., D.C. Tscharke, and A. Simmons. 1994. Up-
regulation of class I major histocompatibility complex gene
expression in primary sensory neurons, satellite cells, and
Schwann cells of mice in response to acute but not latent her-
pes simplex virus infection in vivo. J. Exp. Med. 180:841–
850.
25. Neumann, H., A. Cavalie, D.E. Jenne, and H. Wekerle.
1995. Induction of MHC class I genes in neurons. Science.
269:549–552.
26. Rall, G.F., L. Mucke, and M.B.A. Oldstone. 1995. Conse-
quences of cytotoxic T lymphocyte interaction with major
histocompatibility complex class I–expressing neurons in
vivo.  J. Exp. Med. 182:1201–1212.
27. Mavromara-Nazos, P., S. Silver, J. Hubenthal-Voss, J.L.
McKnight, and B. Roizman. 1986. Regulation of herpes
simplex virus 1 genes: a gene sequence requirements for
transient induction of indicator genes regulated by b or late
(g 2) promoters. Virology. 149:152–164.
Address correspondence to Robert L. Hendricks at his current address, Department of Ophthalmology, Rm.
920, Eye and Ear Institute, University of Pittsburgh Medical Center, 203 Lothrop St., Pittsburgh, PA 15213.
Phone: 412-647-5754; Fax: 412-647-5880; E-mail: bobhend@vision.eei.upmc.edu
Received for publication 14 August 1997 and in revised form 6 November 1997.348 ICP47 Augments Herpes Simplex Virus Neurovirulence
28. Ligas, M.W., and D.C. Johnson. 1988. A herpes simplex vi-
rus mutant in which glycoprotein D sequences are replaced
by b-galactosidase sequences binds to but is unable to pene-
trate into cells. J. Virol. 62:1486–1494.
29. Roller, R.J., and B. Roizman. 1992. The herpes simplex vi-
rus 1 RNA binding protein US11 is a virion component and
associates with ribosomal 60S subunits. J. Virol. 66:3624–
3632.
30. Hendricks, R.L., and J. Sugar. 1984. Lysis of herpes simplex
virus–infected targets. II. Nature of the effector cells. Cell.
Immunol. 83:262–270.
31. Newell, C.K., D. Sendele, and B.T. Rouse. 1989. Effects of
CD41 and CD81 T-lymphocyte depletion on the induction
and expression of herpes simplex stromal keratitis. Reg. Immu-
nol. 2:366–369.
32. Nash, A.A., A. Jayasuriyz, J. Phelan, S.P. Cobbold, and H.
Waldmann. 1987. Different roles for L3T41 and Lyt 21 T
cell subsets in the control of an acute herpes simplex virus in-
fection of the skin and nervous system J. Gen Virol. 68:825–
833.
33. Liu, T., Q. Tang, and R.L. Hendricks. 1996. Inflammatory
infiltration of the trigeminal ganglion after herpes simplex vi-
rus type 1 corneal infection. J. Virol. 70:264–271.
34. Valyi-Nagy, T., M.U. Fareed, J.S. O’Keefe, R.M. Gesser,
A.R. MacLean, S.M. Brown, J.G. Spivack, and N.W. Fraser.
1994 The herpes simplex virkus type 1 strain 171 gamma
34.5 deletion mutant 1716 is avirulent in SCID mice J. Gen.
Virol. 75:2059–2063.
34. Valyi-Nagy, T., R.M. Gesser, B. Raengsakulrach, S. Desh-
mane, B.P. Randazzo, A.J. Dillner, and N.W. Fraser. 1994.
A thymidine kinase-negative HSV-1 strain establishes a per-
sistent infection in SCID mice that features unconrolled pe-
ripheral replication but only marginal nervous system in-
volvement.  Virology. 199:484–490.
35. Dingwell, K.S., L.C. Doering, and D.C. Johnson. 1995. Gly-
coproteins E and I facilitate neuron-to-neuron spread of her-
pes simplex virus. J. Virol. 69:7087–7098.
36. Liu, T., Q. Tang, and R.L. Hendricks. 1996. Inflammatory
infiltration of the trigeminal ganglion after herpes simplex vi-
rus type I corneal infection. J. Virol. 70:264–271.
37. Feduchi, E., M.A. Alonso, and L. Carrasco. 1989. Human g
interferon and tumor necrosis factor exert a synergistic block-
ade on the replication of herpes simplex virus. J. Virol. 63:
1354–1359.
38. Jacobsen, H., J. Mestan, S. Mittnacht, and C.W. Dieffenbach.
1989.  b interferon subtype 1 induction by tumor necrosis
factor. Mol. Cell Biol. 9:3037–3042.
39. Cantin, E.M., D.R. Hinton, J. Chen, and H. Openshaw.
1995.  g  interferon expression during acute and latent nervous
system infection by herpes simplex virus type 1. J. Virol. 69:
4898–4905.
40. Halford, W.P., B.M. Gebhardt, and D.J.J. Carr. 1996. Persis-
tent cytokine expression in trigeminal ganglion latently in-
fected with herpes simplex virus type 1. J. Immunol. 157:
3542–3549.
41. Shimeld, C., J.L. Whiteland, N.A. Williams, D. Easty, and
T.J. Hill. 1996. Reactivation of herpes simplex virus type 1 in
the mouse trigeminal ganglion: an in vivo study of virus anti-
gen and immune cell infiltration. J. Gen. Virol. 77:2583–
2590.
42. Ikemoto, K., R.B. Pollard, T. Fukumoto, M. Morimatsu,
and F. Suzuki. 1995. Small amounts of exogenous IL-4 in-
crease the severity of encephalitis induced in mice by the in-
tranasal infection of herpes simplex virus type 1. J. Immunol.
155:1326–1333.
43. Mitchell, B.M., and J.G. Stevens. 1996. Neuroinvasive prop-
erties of herpes simplex virus type 1 glycoprotein variants are
controlled by the immune response. J. Immunol. 156:246–
255.
44. Nahmias, A.J., and R.M. Coleman. 1984. The significance of
herpes simplex virus infections in humans. In Immunobiol-
ogy of Herpes Simplex Virus Infection. B.T. Rouse and C.
Lopez, editors. CRC Press, Inc., Boca Raton, FL. 1–8.